Filing Flows › Theravance Biopharma (TBPH) › Q2 2026 › vs Q2 2025
Theravance Biopharma (TBPH) Q2 2026 vs Q2 2025 (year over year)
Theravance Biopharma's revenue fell $5.5M (-21%) from $26.2M in Q2 2025 to $20.7M in Q2 2026.
Theravance Biopharma, Q2 2026: revenue $20.7M (-21% year over year), operating margin -39.9%, net loss $5.9M, operating cash flow −$7.0M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $20.7M | $26.2M | −$5.5M | -21% |
| Other income, net | $3.5M | $75.9M | −$72.4M | -95% |
| Net loss | $5.9M | −$54.8M | $60.7M | — |
| Costs & expenses | $30.1M | $102M | −$72.0M | -71% |
| Operating costs | $29.0M | $28.9M | $88K | +0.3% |
| Income tax | $1.1M | $18.4M | −$17.3M | -94% |
| Research & development | $4.7M | $10.5M | −$5.8M | -55% |
| SG&A | $14.2M | $18.4M | −$4.3M | -23% |
| Operating cash sources | $13.0M | −$204M | $216M | — |
| Share-based compensation | $6.0M | $4.5M | $1.4M | +32% |
| Cash used in operations | $7.0M | −$208M | $215M | — |
| Net loss absorbed | $5.9M | −$54.8M | $60.7M | — |
| Working capital & other | $7.1M | −$149M | $156M | — |
Questions
How much did Theravance Biopharma's revenue grow year over year in Q2 2026?
Theravance Biopharma's revenue fell $5.5M (-21%) from $26.2M in Q2 2025 to $20.7M in Q2 2026.